Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial
-
- Geert Leroux-Roels
- Center for Vaccinology, Ghent University and University Hospital, Belgium
-
- Jakob P Cramer
- Takeda Pharmaceuticals International AG, Zurich, Switzerland
-
- Paul M Mendelman
- Takeda Vaccines Inc, Boston, Massachusetts
-
- James Sherwood
- Takeda Pharmaceuticals International AG, Zurich, Switzerland
-
- Ralf Clemens
- Takeda Pharmaceuticals International AG, Zurich, Switzerland
-
- Annelies Aerssens
- Center for Vaccinology, Ghent University and University Hospital, Belgium
-
- Ilse De Coster
- Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
-
- Astrid Borkowski
- Takeda Pharmaceuticals International AG, Zurich, Switzerland
-
- Frank Baehner
- Takeda Pharmaceuticals International AG, Zurich, Switzerland
-
- Pierre Van Damme
- Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
収録刊行物
-
- The Journal of Infectious Diseases
-
The Journal of Infectious Diseases 217 (4), 597-607, 2017-11-13
Oxford University Press (OUP)